CDNA
Get informed when a big investor buys or sells
+ FollowOvervalued by 107.5% based on the discounted cash flow analysis.
| Market cap | $1.18 Billion |
|---|---|
| Enterprise Value | $1.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.4 |
| Beta | 2.49 |
| Outstanding Shares | 51,151,794 |
| P/E Ratio | -142.47 |
|---|---|
| PEG | 112.07 |
| Price to Sales | 2.79 |
| Price to Book Ratio | 3.72 |
| Enterprise Value to Revenue | 2.71 |
| Enterprise Value to EBIT | -102.68 |
| Enterprise Value to Net Income | -137 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 20,300▼ 73.91% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 102.75%▲ 3.41% |
|---|---|
| Total Invested | $911.99M▼ 7.20% |
| Investors Holding | 190▼ 11.00% |
No data
This committee controls taxation, trade, and entitlement spending, crucially including Medicare and Medicaid. Its decisions on reimbursement rates for medical services, including laboratory tests, are a primary financial driver for companies like Caredx.
This committee allocates discretionary federal spending. Its subcommittees determine precise funding for health agencies (NIH, CDC, VA) and research programs, directly impacting the potential for federal contracts and grants that Caredx could receive or benefit from.
This committee directly regulates key agencies like the FDA (which oversees diagnostic tests) and NIH (a major source of medical research funding). Its legislative decisions on health policy, approvals, and research funding directly impact Caredx's industry and operations.
This committee oversees the Department of Veterans Affairs (VA). The VA is a major healthcare provider, and its funding and service decisions directly impact government healthcare contractors, including potential providers of medical lab services like Caredx.